Anti-infective Agents Market Size, Share and Growth Outlook, 2026

Anti-infective Agents Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Anti-infective Agents Market size is forecast to increase from $148.93 Billion in 2026 to $173.13 Billion in 2034 at a CAGR of 1.9% between 2026 and 2034.

The Anti-infective Agents market report provides detailed analysis and outlook of Anti-infective Agents segments including By Drug Type (Antibacterials, Antiviral Drugs, Antifungal Drugs, Antiparasitic Drugs), By Route of Administration (Oral Formulations, Parenteral, Topical, Inhalation and Other Routes), By Application (Community-Acquired Infections, Hospital-Acquired Infections, Chronic Infectious Diseases), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online, Specialty Pharmacies) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Anti-Infective Agents Industry Overview

Innovation in Combating Multidrug-Resistant Bacterial Infections

The anti-infective agents industry is increasingly focused on addressing the global challenge of antimicrobial resistance through the development of advanced antibacterial therapies targeting multidrug-resistant pathogens. A significant advancement is the U.S. FDA approval of Zaynich™ (cefepime and zidebactam), developed by Wockhardt for the treatment of complicated urinary tract infections, including severe pyelonephritis caused by susceptible Gram-negative bacteria. The therapy combines a fourth-generation cephalosporin antibiotic with a novel beta-lactamase enhancer, creating a differentiated approach to overcoming bacterial resistance mechanisms. As healthcare systems face rising rates of resistant infections, pharmaceutical manufacturers are prioritizing combination therapies and next-generation anti-infective agents capable of maintaining effectiveness against increasingly complex bacterial profiles. This focus is driving substantial investment in novel antimicrobial platforms designed to preserve treatment efficacy in critical care and hospital settings.

Strategic Acquisitions Strengthening Anti-Infective Drug Pipelines

The anti-infective agents market is also being shaped by strategic mergers and acquisitions aimed at expanding therapeutic portfolios and accelerating innovation. Asahi Kasei Pharma’s acquisition of AiCuris Anti-infective Cures AG strengthens its position in the global infectious disease sector by integrating advanced antiviral and antibacterial development programs into its pharmaceutical pipeline. AiCuris has established expertise in therapies targeting serious infections affecting immunocompromised and hospitalized patients, making the acquisition particularly valuable in addressing complex infectious disease challenges. The transaction reflects a broader industry trend in which large pharmaceutical companies are seeking to expand capabilities through access to specialized anti-infective technologies, proprietary research platforms, and innovative drug candidates. Such consolidation efforts are enhancing research productivity and expanding the availability of novel treatment options across antibacterial and antiviral therapeutic categories.

Global R&D Priorities Driving Future Antibacterial Development

International health organizations are playing an increasingly important role in guiding anti-infective research and development strategies. The World Health Organization has published updated Target Product Profiles designed to direct global funding and scientific efforts toward priority antibacterial therapies. These frameworks establish detailed safety, pharmacokinetic, and efficacy criteria for the development of treatments targeting multidrug-resistant Gram-negative infections, severe Gram-positive bacterial diseases, and healthcare-associated bacterial meningitis. By defining clear clinical and regulatory objectives, these profiles help align pharmaceutical innovation with urgent public health needs. The growing collaboration among regulators, healthcare organizations, and drug developers is accelerating efforts to address antibiotic resistance while supporting the development of high-priority anti-infective agents for critically ill patient populations.

Anti-infective Agents Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Anti-infective Agents market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Pfizer Inc., Gilead Sciences, Inc., GlaxoSmithKline plc (GSK), Merck & Co., Inc., Johnson & Johnson, Novartis AG (Sandoz), AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Abbott Laboratories. The Anti-infective Agents market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Anti-infective Agents industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Anti-infective Agents Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Anti-infective Agents companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Anti-infective Agents markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Anti-infective Agents Market Competitive Benchmarking and Company Analysis

Leading companies in Anti-infective Agents industry include- Pfizer Inc., Gilead Sciences, Inc., GlaxoSmithKline plc (GSK), Merck & Co., Inc., Johnson & Johnson, Novartis AG (Sandoz), AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Abbott Laboratories. The Anti-infective Agents market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Anti-infective Agents Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Anti-infective Agents market remains one of the strongest-performing segments in the country.
The US Anti-infective Agents Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Anti-infective Agents market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Anti-infective Agents industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Anti-infective Agents markets

Canada's strong Anti-infective Agents sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Anti-infective Agents market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Anti-infective Agents Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Anti-infective Agents market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Anti-infective Agents population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Anti-infective Agents industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Anti-infective Agents market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Anti-infective Agents sales through 2034

France Anti-infective Agents companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Anti-infective Agents Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Anti-infective Agents distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Anti-infective Agents Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Anti-infective Agents market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Anti-infective Agents industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Anti-infective Agents industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Anti-infective Agents Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Anti-infective Agents market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Anti-infective Agents market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Anti-infective Agents Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Anti-infective Agents Market Segmentation

By Drug Type
Antibacterials
Antiviral Drugs
Antifungal Drugs
Antiparasitic Drugs
By Route of Administration
Oral Formulations
Parenteral
Topical
Inhalation and Other Routes
By Application
Community-Acquired Infections
Hospital-Acquired Infections
Chronic Infectious Diseases
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online
Specialty Pharmacies

Top Companies in Anti-infective Agents Industry

Pfizer Inc.
Gilead Sciences, Inc.
GlaxoSmithKline plc (GSK)
Merck & Co., Inc.
Johnson & Johnson
Novartis AG (Sandoz)
AbbVie Inc.
Sanofi S.A.
AstraZeneca PLC
Abbott Laboratories

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa